Literature DB >> 18772236

Aldose reductase regulates high glucose-induced ectodomain shedding of tumor necrosis factor (TNF)-alpha via protein kinase C-delta and TNF-alpha converting enzyme in vascular smooth muscle cells.

Aramati B M Reddy1, Kota V Ramana, Sanjay Srivastava, Aruni Bhatnagar, Satish K Srivastava.   

Abstract

Chronic low-grade inflammation has emerged as a key contributor to the cardiovascular complications of diabetes, however, the mechanisms by which diabetes increases inflammation remain poorly understood. Here, we report that exposure to high glucose (HG) stimulates ectodomain shedding of TNF-alpha from rat aortic smooth muscle cells in culture. Our results show that exposure to HG decreases membrane-associated TNF-alpha. This decrease in unprocessed TNF-alpha was prevented by the aldose reductase (AR) inhibitor sorbinil and AR small interference RNA. Treatment with HG, but not equimolar mannitol or 3-O-methyl glucose, resulted in phosphorylation and activation of TNF-alpha converting enzyme (TACE) (ADAM17), which were attenuated by sorbinil or AR-specific small interference RNA. HG-induced TACE phosphorylation and TNF-alpha processing were also prevented by TNF-alpha protease inhibitor-1, an inhibitor of TACE. Inhibition of protein kinase C (PKC)-delta by rottlerin prevented HG-induced TACE activation and the accumulation of unprocessed TNF-alpha. Treatment with sorbinil decreased elevated levels of circulating TNF-alpha in streptozotocin-treated diabetic rats. Sorbinil treatment also decreased the expression of TNF-alpha, matrix metalloproteinase-2, matrix metalloproteinase-9, and increased tissue inhibitor of metalloproteinase-3 in vascular smooth muscle cells treated with HG and in balloon-injured carotid arteries of diabetic rats. These results indicate that HG-induced TNF-alpha shedding could be attributed to TACE activation, which is regulated, in part, by PKC-delta and AR. Therefore, inhibition of TACE by TNF-alpha protease inhibitor-1, or pharmacological inhibition of PKC-delta or AR may represent useful strategies for treating vascular inflammation associated with diabetes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18772236      PMCID: PMC2630901          DOI: 10.1210/en.2008-0677

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  76 in total

Review 1.  Linking inflammation and atherogenesis: Soluble markers identified for the detection of risk factors and for early risk assessment.

Authors:  James T Wu; Lily L Wu
Journal:  Clin Chim Acta       Date:  2005-12-15       Impact factor: 3.786

2.  Bacterial induction of TNF-alpha converting enzyme expression and IL-6 receptor alpha shedding regulates airway inflammatory signaling.

Authors:  Marisa I Gómez; Sach H Sokol; Amanda B Muir; Grace Soong; Jayson Bastien; Alice S Prince
Journal:  J Immunol       Date:  2005-08-01       Impact factor: 5.422

Review 3.  Inflammation and insulin resistance.

Authors:  Steven E Shoelson; Jongsoon Lee; Allison B Goldfine
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

4.  Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes.

Authors:  Sridevi Devaraj; Nicole Glaser; Steve Griffen; Janice Wang-Polagruto; Eric Miguelino; Ishwarlal Jialal
Journal:  Diabetes       Date:  2006-03       Impact factor: 9.461

5.  Contribution of aldose reductase to diabetic hyperproliferation of vascular smooth muscle cells.

Authors:  Sanjay Srivastava; Kota V Ramana; Ravinder Tammali; Satish K Srivastava; Aruni Bhatnagar
Journal:  Diabetes       Date:  2006-04       Impact factor: 9.461

6.  Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes.

Authors:  Andrea Natali; Elena Toschi; Stephanie Baldeweg; Demetrio Ciociaro; Stefania Favilla; Luigi Saccà; Ele Ferrannini
Journal:  Diabetes       Date:  2006-04       Impact factor: 9.461

7.  The effect of ruboxistaurin on nephropathy in type 2 diabetes.

Authors:  Katherine R Tuttle; George L Bakris; Robert D Toto; Janet B McGill; Kuolung Hu; Pamela W Anderson
Journal:  Diabetes Care       Date:  2005-11       Impact factor: 19.112

Review 8.  Insulin resistance and atherosclerosis.

Authors:  Julie Nigro; Narin Osman; Anthony M Dart; Peter J Little
Journal:  Endocr Rev       Date:  2006-02-21       Impact factor: 19.871

9.  Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes: the Hoorn Study.

Authors:  Jolien de Jager; Jacqueline M Dekker; Adriaan Kooy; Piet J Kostense; Giel Nijpels; Rob J Heine; Lex M Bouter; Coen D A Stehouwer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-03-02       Impact factor: 8.311

10.  Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha.

Authors:  Massimo Federici; Marta L Hribal; Rossella Menghini; Hiroko Kanno; Valentina Marchetti; Ottavia Porzio; Susan W Sunnarborg; Stefano Rizza; Matteo Serino; Veronica Cunsolo; Davide Lauro; Alessandro Mauriello; David S Smookler; Paolo Sbraccia; Giorgio Sesti; David C Lee; Rama Khokha; Domenico Accili; Renato Lauro
Journal:  J Clin Invest       Date:  2005-11-17       Impact factor: 14.808

View more
  28 in total

1.  ADAM17 regulates TNFα production by placental trophoblasts.

Authors:  R Ma; Y Gu; L J Groome; Y Wang
Journal:  Placenta       Date:  2011-10-20       Impact factor: 3.481

Review 2.  ADAM-17: the enzyme that does it all.

Authors:  Monika Gooz
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-04       Impact factor: 8.250

3.  Overexpression of miR-130a-3p/301a-3p attenuates high glucose-induced MPC5 podocyte dysfunction through suppression of TNF-α signaling.

Authors:  Yan Jiang; Wei Wang; Zong-Yang Liu; Yi Xie; Yuan Qian; Xue-Ni Cai
Journal:  Exp Ther Med       Date:  2017-11-08       Impact factor: 2.447

4.  Aldose reductase inhibition prevents endotoxin-induced inflammatory responses in retinal microglia.

Authors:  Kun-Che Chang; Jessica Ponder; Daniel V Labarbera; J Mark Petrash
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-02       Impact factor: 4.799

5.  Aldose Reductase Mediates Transforming Growth Factor β2 (TGF-β2)-Induced Migration and Epithelial-To-Mesenchymal Transition of Lens-Derived Epithelial Cells.

Authors:  Kun-Che Chang; J Mark Petrash
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-07       Impact factor: 4.799

6.  ADAM28 is elevated in humans with the metabolic syndrome and is a novel sheddase of human tumour necrosis factor-α.

Authors:  Jeremy B M Jowett; Yasunori Okada; Peter J Leedman; Joanne E Curran; Matthew P Johnson; Eric K Moses; Harald H H Goring; Satsuki Mochizuki; John Blangero; Leah Stone; Holly Allen; Chris Mitchell; Vance B Matthews
Journal:  Immunol Cell Biol       Date:  2012-09-25       Impact factor: 5.126

7.  ADAM17 mediates Nox4 expression and NADPH oxidase activity in the kidney cortex of OVE26 mice.

Authors:  Bridget M Ford; Assaad A Eid; Monika Göőz; Jeffrey L Barnes; Yves C Gorin; Hanna E Abboud
Journal:  Am J Physiol Renal Physiol       Date:  2013-05-15

8.  Mitochondrial reactive oxygen species mediate GPCR-induced TACE/ADAM17-dependent transforming growth factor-alpha shedding.

Authors:  Timothy J Myers; Leann H Brennaman; Mary Stevenson; Shigeki Higashiyama; William E Russell; David C Lee; Susan Wohler Sunnarborg
Journal:  Mol Biol Cell       Date:  2009-12       Impact factor: 4.138

9.  Regulation of urinary ACE2 in diabetic mice.

Authors:  Jan Wysocki; Laura Garcia-Halpin; Minghao Ye; Christoph Maier; Kurt Sowers; Kevin D Burns; Daniel Batlle
Journal:  Am J Physiol Renal Physiol       Date:  2013-06-12

10.  TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1.

Authors:  Marina Cardellini; Rossella Menghini; Eugenio Martelli; Viviana Casagrande; Arianna Marino; Stefano Rizza; Ottavia Porzio; Alessandro Mauriello; Anna Solini; Arnaldo Ippoliti; Renato Lauro; Franco Folli; Massimo Federici
Journal:  Diabetes       Date:  2009-07-06       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.